阿托瓦斯塔丁和罗斯瓦斯塔丁对ST段升高心肌梗塞患者功能障碍冠状动脉循环的作用
Langping Zhou1, Xiangming Hu1,2, Haotian Zhang1
1Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
The Journal of international medical research
|June 28, 2023
概括
阿托瓦斯塔丁改善了ST段升高心肌梗塞 (STEMI) 患者的冠状动脉微循环 perfusion 在初级穿皮冠状动脉干预 (pPCI) 后,与罗斯瓦斯塔丁不同. 这表明阿托瓦斯塔丁可能对这个患者群体更有效.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 干预心脏病学 干预心脏病学
背景情况:
- 功能障碍的冠状动脉循环是ST段升高心肌梗塞 (STEMI) 患者接受初级皮肤穿冠状动脉干预 (pPCI) 的关注点.
- 关于不同类型的他类药物对这些患者冠状动脉微循环的比较作用的证据有限.
研究的目的:
- 为了比较阿托瓦斯塔丁与罗斯瓦斯塔丁在改善STEMI患者的功能障碍冠状动脉循环后的疗效.
- 评估他类药物治疗对冠状动脉微血管功能的影响.
主要方法:
- 对597名接受pPCI的STEMI患者进行了回顾性研究.
- 功能障碍的冠状动脉循环评估使用心肌梗塞中血栓分析 (TIMI) 级和TIMI心肌 perfusion 级 (TMPG).
- 后勤回归分析以确定他类型对冠状动脉微循环的影响.
主要成果:
- 在阿托瓦斯塔丁和罗斯瓦斯塔丁组之间,TIMI no/slow reflow没有显著差异.
- 与罗斯瓦斯塔丁 (57.69%) 相比,阿托瓦斯塔丁 (44.58%) 的TMPG无/缓慢回流发生率明显降低 (57.69%).
- 罗斯瓦斯塔丁与TMPG无/缓慢回流的几率增加有关 (OR 1.72-1.73). 临床结果没有差异.
结论:
- 在接受pPCI的STEMI患者中,阿托瓦斯塔丁在改善冠状动脉微循环输液方面表现出优异的结果,与罗斯瓦斯塔丁相比.
- 这些发现突显了在MI后的他类药物对微血管功能影响的潜在差异.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
706
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
706
01:27Coronary Artery Disease V: Interprofessional Care
11
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
11
01:28Acute Coronary Syndrome IV: Interprofessional Care
13
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
13
01:30Acute Coronary Syndrome I: Introduction
33
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
33
01:26Coronary Artery Disease II: Pathophysiology
15
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
15
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
22
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
22